Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial [published online November 12]. JAMA. 2020. doi: 10.1001/jama.2020.22760.

The Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for fluvoxamine maleate for COVID-19 treatment due to insufficient data supporting its use. The ...

Participants were randomized in a 1:1 ratio to receive either fluvoxamine (50 mg twice daily on day 1, followed by 100 mg twice daily for 12 days) or placebo, with study drugs delivered directly ...